Glioma patients who used DEX had the lowest CD4 T, CD8 T, B, NK, monocyte and total lymphocyte cell fractions as well as CD4/CD8 ratio and LMR, and the highest neutrophil fractions and NLR (Fig. 2; Supplemental Table 5). This evidence concerns the gene CD8A and central nervous system cancer.